DoH Policies screened during the period: 1st January 2018 - 31st March 2018
Topics:
Date published:
In fulfilling its obligations under Section 75 the Department is required to equality screen all of its policies and services under consideration to determine whether they should be subject to a full equality impact assessment (EQIA).
Documents
- NICE Technology Appraisal TA493 - Cladribine tablets for treating relapsing-remitting multiple sclerosis
- NICE Technology Appraisal TA494 - Naltrexone–bupropion for managing overweight and obesity
- NICE Technology Appraisal TA495 - Palbociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer
- NICE Technology Appraisal TA496 - Ribociclib in combination with an aromatase inhibitor for previously untreated advanced or metastatic hormone receptor-positive, HER2-negative breast cancer
- NICE Clinical Guideline CG28 - Depression in children and young people: identification and management
- NICE Clinical Guideline NG77 - Cataracts in adults: management
- NICE Clinical Guideline NG78 - Cystic fibrosis: diagnosis and management
- NICE Clinical Guideline NG81 - Glaucoma: diagnosis and management (updates & replaces CG85
- NICE Technology Appraisal TA497 - Golimumab for treating non-radiographic axial spondyloarthritis
- NICE Clinical Guideline NG80 - Asthma: diagnosis, monitoring and chronic asthma management
- NICE Technology Appraisal TA498 - Lenvatinib with everolimus for previously treated advanced renal cell carcinoma
- NICE Technology Appraisal TA499 - Glecaprevir–pibrentasvir for treating chronic hepatitis C
- NICE Technology Appraisal TA502 - Ibrutinib for treating relapsed or refractory mantle cell lymphoma
- NICE Technology Appraisal TA503 - Fulvestrant for untreated locally advanced or metastatic oestrogen-receptor positive breast cancer
- NICE Technology Appraisal TA500 - Ceritinib for untreated ALK-positive non-small-cell lung cancer
- NICE Technology Appraisal TA501 - Intrabeam radiotherapy system for adjuvant treatment of early breast cancer
- NICE Technology Appraisal TA504 - Pirfenidone for treating idiopathic pulmonary fibrosis (review of TA282)
- NICE Technology Appraisal TA506 - Lesinurad for treating chronic hyperuricaemia in people with gout
- NICE Technology Appraisal TA508 - Autologous chondrocyte implantation using chondrosphere for treating symptomatic articular cartilage defects of the knee
- NICE Technology Appraisal TA507 - Sofosbuvir–velpatasvir–voxilaprevir for treating chronic hepatitis C
- NICE Clinical Guideline NG83 - Oesophago-gastric cancer: assessment and management in adults
- Proposed Ionising Radiation (Medical Exposure) Regulations (Northern Ireland) 2018 and underpinning policy